Atossa Therapeutics Plans to Issue Stapled CVR for Shareholders
Atossa Therapeutics announced plans to issue contingent value rights tied to a potential rare pediatric disease priority review voucher.
Atossa Therapeutics announced plans to issue contingent value rights tied to a potential rare pediatric disease priority review voucher.